Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: A meta-analysis

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Dai, Meiyu ^a   Chen, Xiaoli ^a   Liu, Xuexiang ^a   Peng, Zheng ^a   Meng, Jie ^a   Dai, Shengming ^a   Sethi, Gautam ^b  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CELL PROTEIN; GOLGI PROTEIN 73; UNCLASSIFIED DRUG; AFP PROTEIN, HUMAN; GOLM1 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS (TOPIC); PUBLISHING; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; BLOOD; CARCINOMA, HEPATOCELLULAR; GOLGI COMPLEX; LIVER; LIVER NEOPLASMS; META ANALYSIS; PATHOLOGY;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; GOLGI APPARATUS; HUMANS; LIVER; LIVER NEOPLASMS; MEMBRANE PROTEINS; REGRESSION ANALYSIS;

EID: 84947736969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140067     Document Type: Article

References (39)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29. doi: 10.3322/caac.20138 PMID: 22237781
2. Thun MJ, DeLancey JO, Center M.M., Jemal A., Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31:100-110. doi: 10.1093/carcin/bgp263 PMID: 19934210
3. Njei B, Rotman Y, Ditah I., Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015; 61:191-199. doi: 10.1002/hep.27388 PMID: 25142309
4. Zhang ZM, Zhang YM, Yao F, Yi P., Huang S, Liu JY, et al Analysis on postoperative efficacy of radical hepatectomy for patients with non-HBV/HCV hepatocellular carcinoma. Asian Pac J Cancer Prev. 2015; 16:3479-3483. PMID: 25921165
5. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J. 2009; 122: 3-4. PMID: 19187608
6. Ertle JM, Heider D, Wichert M., Keller B, Kueper R, Hilgard P., et al. A combination of ofetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013; 87: 121-131. doi: 10.1159/000346080 PMID: 23406785
7. Yamamoto K, Imamura H, Matsuyama Y., Hasegawa K, Beck Y, Sugawara Y., et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009; 16: 2795-2804. doi: 10.1245/s10434-009-0618-y PMID: 19669841
8. Morimoto M, Numata K, Nozaki A., Kondo M, Moriya S, Taguri M., et al. Novel lens culinaris agglutinin-reactive fraction of ofetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low ofetoprotein concentrations. Int J Clin Oncol. 2012; 17: 373-379. doi: 10.1007/s10147-011-0306-3 PMID: 21847534
9. Shi Y, Chen J, Li L., Sun Z, Zen L, Xu S., et al. A study of diagnostic value of Golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat. 2011; 10: 287-294. PMID: 21517136
10. Block TM, Comunale MA, Lowman M, Steel L.F., Romano PR, Fimmel C, et al. Use of targeted glycoproteins to identify serum glycoproteins that correlated with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA. 2005; 102: 779-784. PMID: 15642945
11. Kladney RD, Bulla GA, Guo L, Mason A.L., Tollefson AE, Simon DJ, et al. GP73, a novel Golgilocalized protein upregulated by viral infection. Gene. 2000; 249: 53-65. PMID: 10831838
12. Kladney RD, Cui X, Bulla G.A., Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology. 2002; 35:1431-1440. PMID: 12029628
13. Schwegler EE, Cazares L, Steel L.F., Adam BL, Johnson DA, Semmes OJ, et al SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology. 2005; 41: 634-642. PMID: 15726646
14. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Gräff A, Gusmirovic I, Solomon H, et al. Disease-and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol. 2004; 99:1087-1095. PMID: 15180730
15. Maitra A, Thuluvgth PJ GP73and liver disease: a (Golgi) complex enigma. Am J Gastroenterol. 2004; 99:1096-1098. PMID: 15180731
16. Ma C, Zhang Q, Qu J., Zhao X, Li X, Liu Y., et al. A precise approach in large scale core-fucosylated glycoprotein identification with low-and high-normalized collision energy. J Proteomics. 2015; 114: 61-70. doi: 10.1016/j.jprot.2014.09.001 PMID: 25220145
17. Whiting P, Rutjes AW, Reitsma J.B., Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003; 10: 3-25.
18. Jia Z, Wang L, Liu C., Yu Z, Chai L, Zhao M. Evaluation of ofetoprotein-L3and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014; 18:192-196.
19. Wang Y, Yang H, Xu H., Lu X, Sang X, Zhong S., et al. Golgi protein 73, notglypican-3, may be atumor marker complementary to ofetoprotein for hepatocellular carcinoma diagnosis. J Gastroenterol Hepatol. 2014; 29: 597-602. doi: 10.1111/jgh.12461 PMID: 24236824
20. Hou SC, Xiao MB, Ni R.Z., Ni WK, Jiang F, Li XY, et al Serum GP73 is complementary to AFP and GGT-II for the diagnosis of hepatocellular carcinoma. Oncol Lett. 2013; 6:1152-1158. PMID: 24137480
21. Morota K, Nakagawa M, Sekiya R, Hemken P.M., Sokoll LJ, Elliott D, et al. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Clin Chem Lab Med. 2011; 49: 711-718. doi: 10.1515/CCLM.2011.097 PMID: 21231906
22. Tian L, Wang Y, Xu D., Gui J, Jia X, Tong H., et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer. 2011; 129:1923-1931. doi: 10.1002/ijc.25838 PMID: 21140449
23. Ozkan H, Erdal H, Tutkak H., Karaeren Z, Yakut M, Yüksel O, et al. Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma. Digestion. 2011; 83: 83-88. doi: 10.1159/000320379 PMID: 21042019
24. Mao Y, Yang H, Xu H., Lu X, Sang X, Du S., et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut. 2010; 59:1687-1693. doi: 10.1136/gut.2010.214916 PMID: 20876776
25. Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010; 27: 339-345. doi: 10.1007/s12032-009-9215-y PMID: 19399652
26. Wang M, Long RE, Comunale M.A., Junaidi O., Marrero J, Di Bisceglie AM, et al. Novel fucosylated bio-markers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009; 18:1914-1921. doi: 10.1158/1055-9965. EPI-08-0980 PMID: 19454616
27. Marrero JA, Romano PR, Nikolaeva O, Steel L., Mehta A, Fimmel CJ, et al GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005; 43:1007-1012. PMID: 16137783
28. Whiting P, Harbord R, Kleijnen J. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol. 2005; 5: 19. PMID: 15918898
29. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002; 21:1237-1256. PMID: 12111876
30. Lijmer JG, Bossuyt PM, Heisterkamp SH Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med. 2002; 21:1525-1537. PMID: 12111918
31. Zhou Y, Yin X, Ying J., Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012; 16:12-17.
32. Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013; 7: 59-64. doi: 10.1007/s12072-012-9374-3 PMID: 23519638
33. Duval S, Tweedie R. Trim and fill: a simple funnel-plot based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56: 455-463. PMID: 10877304
34. Yang J, Li J, Dai W., Wang F, Shen M, Chen K., et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. ExpTherMed. 2015; 9:1413-1420. PMID: 25780444
35. Li YW, Chen ZG, Wang J.C., Zhang ZM. Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: systematic review and meta-analysis. World J Gastroenterol. 2015; 21: 4334-4344. doi: 10.3748/wjg.v21.i14.4334 PMID: 25892885
36. Jia X, Liu J, Gao Y., Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Arch Med Res. 2014; 45: 580-588. doi: 10.1016/j.arcmed.2014.11.002 PMID: 25446613
37. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539-1558. PMID: 12111919
38. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58: 882-893. PMID: 16085191
39. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM Cochrane diagnostic test accuracy working group: systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008; 149: 889-897. PMID: 19075208